Core Viewpoint - The Hong Kong pharmaceutical sector continues to rise, with the Hang Seng Biotechnology Index increasing by over 2%, indicating strong market performance in the biotech industry [1] Group 1: Market Performance - The largest ETF in the Hang Seng Biotechnology Index, the Hang Seng Pharmaceutical ETF (159892), is following the upward trend [1] - Notable stocks such as First Signal Pharmaceuticals surged by over 9%, while companies like Yuan Da Pharmaceutical, Kangfang Biotech, and King’s Ray Biotech led the gains [1] - WuXi AppTec, WuXi AppTec Holdings, and WuXi Biologics experienced slight adjustments in their stock prices [1] Group 2: Index and Futures Development - The Hang Seng Biotechnology Index was launched by the Hang Seng Index Company in 2019 to reflect the overall performance of the Hong Kong biotech market, capturing the entire innovation drug supply chain [1] - The Hong Kong Stock Exchange announced plans to launch futures for the Hang Seng Biotechnology Index on October 14, 2023, enhancing its derivatives ecosystem [1] - The new futures contract is set to begin trading on November 28, 2025, providing investors with precise risk management tools, making it the only index in the Hong Kong pharmaceutical and healthcare sector with index futures [1]